Safety and efficacy of the Oxford-AstraZeneca vaccine against SARS-CoV-2 after 2nd and 3rd dose in adults: a cross-sectional study
Background: The rapid global spread of the coronavirus SARS-CoV-2 and the lack of established therapeutic choices led to development of several vaccines. Our aim was to investigate the safety and effectiveness of the Oxford-AstraZeneca adenovirus vectored vaccine against SARS-CoV-2 breakthrough infe...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical University of Gdańsk
2024-12-01
|
| Series: | European Journal of Translational and Clinical Medicine |
| Subjects: | |
| Online Access: | https://ejtcm.gumed.edu.pl/articles/196493.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: The rapid global spread of the coronavirus SARS-CoV-2 and the lack of established therapeutic choices led to development of several vaccines. Our aim was to investigate the safety and effectiveness of the Oxford-AstraZeneca adenovirus vectored vaccine against SARS-CoV-2 breakthrough infections in people who were vaccinated with 2 or 3 doses of it.
Methods: This cross-sectional study was conducted from February 2021 to September 2021 on 997 people, who had received at least 2 doses of the Oxford-AstraZeneca vaccine. Demographic and clinical data were recorded using a questionnaire. The effectiveness of the vaccine was calculated based on the percentage of vaccinated people with confirmed and probable cases of SARS-CoV-2 infection. SPSS software was used for data analysis, and a significance level of p < 0.05 was chosen.
Results: After vaccination with the 2<sup>nd</sup> and 3<sup>rd</sup> doses, 355 (35.6%) and 26 (8.3%) participants contracted the SARS-CoV-2 infection, respectively. Breakthrough infection after the 2<sup>nd</sup> dose was significantly higher in females (p < 0.001), those with older age (p = 0.021), diabetes (p = 0.003) and hypertension (p < 0.001). Additionally, a significant correlation was found between SARS-CoV-2 infection after the 3<sup>rd</sup> dose and chronic kidney disease (p = 0.022) and a history of infection after the second dose (p < 0.001). The prevalence of vaccine side effects after the 2<sup>nd</sup> and 3<sup>rd</sup> doses was 51.7% and 13.4%, respectively.
Conclusions: The effectiveness of the Oxford-AstraZeneca vaccine in preventing SARS-CoV-2 increased from 64.4% after 2 doses to 91.7% after the 3<sup>rd</sup> dose, therefore it is recommended to administer a 3<sup>rd</sup> dose to ensure strong immunity against SARS-CoV-2. Based on our data the safety of this vaccine is acceptable. |
|---|---|
| ISSN: | 2657-3148 2657-3156 |